Pigmented Villonodular Synovitis - Pipeline Review, H1 2020

May 2020 | 76 pages | ID: P7448065117EN
Global Markets Direct

Abstracts

Pigmented Villonodular Synovitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis – Pipeline Review, H1 2020, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape.

Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively.

Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Pigmented Villonodular Synovitis - Overview
Pigmented Villonodular Synovitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pigmented Villonodular Synovitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Checkmate Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Nippon Chemiphar Co Ltd
Novartis AG
Pigmented Villonodular Synovitis - Drug Profiles
avelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabiralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zaltoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pigmented Villonodular Synovitis - Dormant Projects
Pigmented Villonodular Synovitis - Discontinued Products
Pigmented Villonodular Synovitis - Product Development Milestones
Featured News & Press Releases
Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Pigmented Villonodular Synovitis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pigmented Villonodular Synovitis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Pigmented Villonodular Synovitis - Pipeline by Checkmate Pharmaceuticals Inc, H1 2020
Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pigmented Villonodular Synovitis - Pipeline by Merck KGaA, H1 2020
Pigmented Villonodular Synovitis - Pipeline by Nippon Chemiphar Co Ltd, H1 2020
Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H1 2020
Pigmented Villonodular Synovitis - Dormant Projects, H1 2020
Pigmented Villonodular Synovitis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pigmented Villonodular Synovitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Bristol-Myers Squibb Co
Checkmate Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Nippon Chemiphar Co Ltd
Novartis AG